Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 22, 2018
Pharmacy Choice - News - Pharmaceutical Development - April 22, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/22/18 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 11759) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Arthritis Advisory Committee to discuss new drug application 207924, for baricitinib tablets, submitted by Eli Lilly and Company, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate resp
4/22/18 - Livingston mom battles breast cancer with experimental treatments to help other patients [Detroit Free Press]
Kimberlie Newton can't wallow in the agony of regret. She has enrolled in a clinical trial at the Barbara Ann Karmanos Cancer Institute, hoping that by trying experimental drugs and therapies that have yet to be approved by the U.S. Food and Drug Administration, she might find something new that will give her more time with her husband and son.
4/22/18 - New Findings from Wilhelminen Hospital in Heart Disease Provides New Insights (Uric acid is associated with long-term adverse cardiovascular outcomes...
New Findings from Wilhelminen Hospital in Heart Disease Provides New Insights. By a News Reporter-Staff News Editor at Heart Disease Weekly Current study results on Heart Disorders and Diseases- Heart Disease have been published. The news correspondents obtained a quote from the research from Wilhelminen Hospital, "As primary endpoint, we assesse
4/21/18 - 10xBio Raises $2.7M to Test Body Sculpting Drug in Clinical Trial [Syrian Arab News Agency]
John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup hes leading has raised $2.66 million to advance a drug that is already approved to shrink varicose veins through early-stage clinical trials testing it in a new use fat reduction body sculpting. The biotech, 10 xBio, announced earlier this month that the FDA had approv
4/21/18 - 14501 - Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved, Make of Meditronics or Synthes or Zimmer only. 16038 - Polyaxial Pedicular Screw with Head and Locking, 4.0 Mm -
Ministry/Department Ministry of Railways Dr. Babasaheb Ambedekar Memorial Hospital, Central Railway Dr Ambedekar Road, Byculla East MUMBAI Attn: Md/Byculla-Medical/Central Rly. Description: Tenders are invited for 14501- Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved,
4/21/18 - Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease [All Iraq News Agency (AIN)]
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-202 for...
4/21/18 - An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
GW Pharmaceuticals plc's cannabis-based drug for epilepsy, Epidiolex, won the unanimous backing of an advisory panel to the FDA on April 19, 2018. The FDA's final decision on Epidiolex is expected by June 27, 2018. If approved, Epidiolex would be the first-ever medicine derived from a marijuana plant to be greenlighted by the FDA.
4/21/18 - AZs Tagrisso approved for untreated lung cancer in US [Tehran Times (Iran)]
AstraZenecas Tagrisso looks set to gain further traction after the FDA approved it in first-line treatment for lung cancer patients with a certain mutation. Dr Suresh Ramalingam, principal investigator of the FLAURA trial, from Winship Cancer Institute of Emory University, Atlanta, said: The approval of osimertinib in the first-line setting represe
4/21/18 - Bluebird Bio One Step Closer to First Approved Drug [Arab News (Saudi Arabia)]
Bluebird bio, headquartered in Cambridge, Massachusetts, announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia. The two studies are Northstar, which was recently completed, and HGB-205, which is still proceeding. These interim data demonstrate the potential of...
4/21/18 - Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd., Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery..
4/21/18 - Drugmakers compete to develop liver drugs [All Iraq News Agency (AIN)]
To widen live treatment options, Pharmicell, HLB Life Science, SillaJen, Samil Pharmaceutical, and Hanmi Pharmaceutical are accelerating researches on various drug candidates. Pharmicell, which has a stem cell treatment called Hearticellgram, is waiting to obtain conditional approval for Cellgram LC, a stem cell therapy for cirrhosis.
4/21/18 - Expanding Conditional Approvals in Animal Drug User Fee Act Is Bad for Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
4/21/18 - Expanding Conditional Approvals in the Animal Drug User Fee Act Is Bad For Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
4/21/18 - FDA approves first contact lens that gets darker in sunlight [Tehran Times (Iran)]
The U.S. Food and Drug Administration has signed off on the first ever transition contact lenses, which will get darker when the wearer is out in sunlight. The Acuvue Oasys transition contact lenses are from Johnson& Johnson Vision Care, Inc.. Johnson& Johnson says the new lenses will hit the market during the "first half of 2019.".
4/21/18 - FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia [Sudan Tribune]
The U.S Food and Drug Administration has approved Crysvita, the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia, a rare, inherited form of rickets. XLH differs from other forms of rickets in that vitamin D therapy is not effective, stated Dr Julie Beitz, director of the Office of Drug Evaluation
4/21/18 - FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment [T-break Tech (Middle East)]
Fostamatinib disodium hexahydrate, a kinase inhibitor, was granted FDA approval for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had insufficient response to a previous treatment. Recommended dose is 100 mg orally twice daily. If a platelet count of at least 50109/ L is not achieved in 1 month af
4/21/18 - FDA Approves Osimertinib for Treatment of Non-Small Cell Lung Cancer [Tehran Times (Iran)]
Officials with the FDA have approved osimertinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations, according to a press release. Osimertinib is already approved in the United States for the second-line treatment of patients with metastatic EGFRm NSCLC,..
4/21/18 - FDA clears first therapy for inherited rickets [Sudan Tribune]
US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia, a rare, inherited form of rickets. Ultragenyx Pharmaceutical and Kyowa Hakko Kirins Crysvita is an antibody that blocks fibroblast growth factor 23, a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by t
4/21/18 - Global Wearable Heart Monitoring Devices Market Analysis and Forecast by Recent Trends, Growth and Top Companies With Excellent CAGR growth of 9.4% by 2025
"Global Wearable Heart Monitoring Devices Market Industry Trends" Global Wearable Heart Monitoring Devices industry growing at a CAGR of 9.4% during the forecast period of 2018 to 2025, By Type, Application, End Users Heart ailments is an overall issue and have brought about physical brokenness and passings of the human. These days, specialists are
4/21/18 - Grassley seeks information from HHS, FDA on unproven medical procedures touted as clinical trials [Syrian Arab News Agency]
Chuck Grassley of Iowa sent a letter to Department of Health and Human Services Secretary Alex Azar and Food and Drug Administration Commissioner Dr. A March 15, 2017 Washington Post report detailed three women in South Florida who participated in what they believed was a government-backed clinical trial to reverse the effects of macular degenerati
4/21/18 - Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO (fosnetupitant/ palonosetron) in the United States
-Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO in the United States. Lugano, Switzerland April 20, 2018- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration has approved the intravenous formulation of AKYNZEO as an alternative
4/21/18 - Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE for Opioid Drug Dependence [Sport360]
-Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved PROBUPHINE for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support. The approval of PROBUPHINE...
4/21/18 - Molecular Partners Presented Preliminary Results from the Ongoing Phase 2 Study of MP0250 at the European Myeloma Network Meeting in Turin
ZURICH- SCHLIEREN, SWITZERLAND/ ACCESSWIRE/ April 21, 2018/ Molecular Partners AG, a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, announced today that preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in patients with relapsed refractory multiple.
4/21/18 - Motif closes in on approvals, potentially looking for partnership opportunities [Arab Times (Kuwait)]
In the world of US drug approvals, a positive result in a Phase 3 drug trial is generally celebrated with flourish: it might feel like you are nearing the end of the track. The finish line is near. As Graham Lumsden, chief executive of Motif Bio Plc knows all too well, getting a drug to market is no small task.
4/21/18 - Nanodisc-delivered cancer treatment helps eliminate tumors [T-break Tech (Middle East)]
In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol." Researchers at the University of Michigan Rogel Cancer Center designed this new delivery system a drug hidden in a nanodisc to increase the number of patients who can be treated successfully with c
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415